Lung cancer research focuses on understanding risk factors, improving early detection, refining classification, and expanding treatment options.

Studies show that tobacco smoke remains the main risk factor, but air pollution, occupational exposures, and genetic susceptibility also play major roles. Researchers are mapping how mutations in genes such as EGFR, ALK, and KRAS drive tumor growth, which has led to targeted therapies that block specific molecular pathways. Work is ongoing to identify additional actionable mutations and to overcome resistance that often develops during treatment.

Early detection is a major challenge because symptoms typically appear late. Low dose computed tomography is being evaluated and implemented for screening people at high risk, such as long term smokers, to find tumors when they are still localized and more treatable. There is parallel research on blood based biomarkers and circulating tumor DNA that could enable minimally invasive screening and monitoring.

Lung cancer is increasingly viewed not as a single disease but as a collection of distinct subtypes. Non small cell lung cancer and small cell lung cancer differ in biology, typical mutations, and response to therapy. Within non small cell lung cancer, further molecular subgroups guide selection of targeted drugs and immunotherapies.

Immunotherapy, particularly immune checkpoint inhibitors targeting PD 1, PD L1, and CTLA 4, has transformed the outlook for some patients by activating the immune system against tumor cells. Combination approaches, including chemotherapy, targeted therapy, radiotherapy, and immunotherapy, are being optimized to maximize survival, manage side effects, and tailor treatment to individual tumor profiles and patient characteristics.